Alexo Therapeutics is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Alexo Therapeutics is a Preclinical Stage Biotechnology Company Developing Innovative Immuno-Oncology Therapies for Cancer.

Targeted Phagocytosis: Alexo’s SIRP-alpha variants could serve as universal adjuvants for mAbs to increase macrophage phagocytosis of cancer cells.  Read article

We are a company dedicated to developing novel biologics that are both safe and efficacious for use in combination with anticancer antibodies to help the immune system eradicate cancer. Our first program targets CD47, a protein which acts through its receptor, signal regulatory protein-α (SIRPα), to provide a “don’t eat me” signal to macrophages. Many types of cancers over-express CD47, evading phagocytosis by macrophages. We have identified clinical candidates that block CD47 signaling without causing macrophages to attack normal healthy cells. The presence of CD47 on cancer cells limits the effectiveness of many widely used antibodies for cancer. We are creating multiple approaches to discover and develop therapies that will significantly increase the therapeutic potential of a variety of anticancer antibodies.